HFS
ESPR

HL Financial Services’s Esperion Therapeutics ESPR Stock Holding History

HL Financial Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$684K Buy
+17,040
New +$764K 0.01% 438

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HL Financial Services's ESPR Position: Q1 2019 in Review

HL Financial Services opened a new position in Esperion Therapeutics (ESPR) in Q1 2019: 17,040 shares worth $684K. The stake represents 0.01% of the portfolio and ranks #438 among its holdings.

163 funds tracked by Wall St. Rank hold ESPR as of Q1 2019.

  • HL Financial Services held 17,040 shares of Esperion Therapeutics worth $684K as of Q1 2019.
  • Esperion Therapeutics was a new HL Financial Services position in Q1 2019.
  • Esperion Therapeutics made up 0.01% of HL Financial Services's portfolio in Q1 2019, its #438 holding.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2019.

Based on HL Financial Services's 13F filing for Q1 2019, filed 1 May 2019.